Related Experiment Video
Updated: Jul 2, 2026
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Targeting angiogenesis in renal cell carcinoma
Georgios Lainakis1, Aristotle Bamias
1Dept. of Clinical Therapeutics, Medical School, University of Athens, 15235 Athens, Greece.
Current Cancer Drug Targets
|August 12, 2008
Summary
Targeting angiogenesis, crucial for renal cell carcinoma (RCC) progression, offers new hope. Novel anti-angiogenic therapies show significant promise for advanced kidney cancer, outperforming older treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis is vital for cancer growth and spread.
- Renal cell carcinoma (RCC) involves Von-Hippel Lindau (VHL) gene inactivation, leading to hypoxia-inducible factor-alpha (HIFa) hyperactivity.
- HIFa drives production of angiogenic factors like VEGF and PDGF, promoting tumor growth and metastasis.
Purpose of the Study:
- To review recent advancements in biological agents for advanced renal cell carcinoma treatment.
- To highlight the role of anti-angiogenic therapies in managing this disease.
Main Methods:
- Review of clinical trials and approved therapies for advanced renal cell carcinoma.
- Focus on biological agents targeting angiogenesis.
Main Results:
- New biological agents (Sunitinib, Bevacizumab, Sorafenib, Temserolimus) demonstrate significant activity in advanced RCC.
- These agents, targeting angiogenesis, are more effective than traditional cytokine therapy (interferon, interleukin).
- Bevacizumab is an anti-VEGF antibody; Sunitinib and Sorafenib are multi-tyrosine kinase inhibitors (TKIs); Temserolimus is an mTOR inhibitor.
Conclusions:
- Angiogenic factors are promising therapeutic targets in renal cell carcinoma.
- Novel anti-angiogenic agents represent a significant advancement over historical treatments for advanced RCC.
- Ongoing clinical research continues to explore and refine these targeted therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...